Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous bone marrow aspirate concentrate (BMAC) for no-option critical limb ischemia in type 2 diabetes mellitus (DILAEG)
2012-001825-28Phase 3Terminated
- Sponsor
- University Hospital Ostrava
- Start
- Aug 2012
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised trial of autologous bone marrow cell concentrate in chronic limb-threatening ischemia (CLTI), type 2 diabetes mellitus (T2DM) and diabetic foot ulcer (DFU) (2 arms), sponsored by University Hospital Ostrava. Started Aug 2012; status: terminated.
02
Drugs
autologous bone marrow cell concentrate
03
Conditions
chronic limb-threatening ischemia (CLTI)type 2 diabetes mellitus (T2DM)diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on 2012-001825-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001825-28.